Hematopoietic Neoplasm/Leukemia - Myelodysplastic Syndrome

NCT00046930

Clinical Trial Information

Trial Number: NCT00046930 (ClinicalTrials.gov)

Disease Type:

Hematopoietic Neoplasm/Leukemia - Acute Myeloid Leukemia
Hematopoietic Neoplasm/Leukemia - Myelodysplastic Syndrome

Trial Title:

A Randomized, Placebo-Controlled, Double Blind, Trial of the Administration of the MDR Modulator, Zosuquidar Trihydrochloride (LY335979), During Conventional Induction and Post-Remission Therapy in Patients Greater Than 60 Years of Age With Newly Diagnosed Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts in Transformation or High-Risk Refractory Anemia With Excess Blasts

Study ID:

E3999

Images are available?:

Is this a NCI-MATCH Trial?:

Datasets Linked to Trial

Title	Description
NCT00046930-D4	There are four different submissions (each for 227 patients) for PMID 37407550 (a correction for PMID 36151075) from the trial E3999. This dataset, NCT00046930-D4, contains the second set of mutation data. Dataset NCT00046930-D1, contains baseline, treatment, and efficacy data. Dataset NCT00046930-D2 contains cytogenetic data. Dataset NCT00046930-D3 contains the first set of mutation data.
NCT00046930-D3	There are four different submissions (each for 227 patients) for PMID 37407550 (a correction for PMID 36151075) from the trial E3999. This dataset, NCT00046930-D3, contains the first set of mutation data. Dataset NCT00046930-D1, contains baseline, treatment, and efficacy data. Dataset NCT00046930-D2 contains cytogenetic data. Dataset NCT00046930-D4 contains the second set of mutation data.
NCT00046930-D2	There are four different submissions (each for 227 patients) for PMID 37407550 (a correction for PMID 36151075) from the trial E3999. This dataset, NCT00046930-D2, contains cytogenetic data. Dataset NCT00046930-D1 contains baseline, treatment, and efficacy. Dataset NCT00046930-D3 contains the first set of mutation data. Dataset NCT00046930-D4 contains the second set of mutation data.
NCT00046930-D1	There are four different submissions (each for 227 patients) for PMID 37407550 (a correction for PMID 36151075) from the trial E3999. This dataset, NCT00046930-D1, contains baseline, treatment, and efficacy data. Dataset NCT00046930-D2 contains cytogenetic data. Dataset NCT00046930-D3 contains the first set of mutation data. Dataset NCT00046930-D4 contains the second set of mutation data.

NCT00843882

Clinical Trial Information

Trial Number: NCT00843882 (ClinicalTrials.gov)

Disease Type:

Hematopoietic Neoplasm/Leukemia - Myelodysplastic Syndrome

Trial Title:

Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and in Combination with Epoetin Alfa (Procrit®) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia

Study ID:

E2905

Images are available?:

Is this a NCI-MATCH Trial?:

Datasets Linked to Trial

NCT02521493

Clinical Trial Information

Trial Number: NCT02521493 (ClinicalTrials.gov)

Disease Type:

Hematopoietic Neoplasm/Leukemia - Acute Myeloid Leukemia
Hematopoietic Neoplasm/Leukemia - Myelodysplastic Syndrome

Trial Title:

Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Study ID:

AAML1531

Images are available?:

Is this a NCI-MATCH Trial?:

Datasets Linked to Trial

Title	Description
NCT02521493-D2	NCT02521493-D2 Dataset There are 2 datasets associated with PMID 34320162, NCT02521493-D1 through NCT02521493-D2. The NCT02521493-D2 dataset is an adverse event level dataset (single row per adverse event, period, and patient) containing information of the micro-organisms associated with adverse events by period in the AAML1531 clinical trial.
NCT02521493-D1	NCT02521493-D1 Dataset There are 2 datasets associated with PMID 34320162, NCT02521493-D1 through NCT02521493-D2. The NCT02521493-D1 dataset is a patient level dataset (single row per patient) containing patient characteristics, laboratory findings, and outcome for eligible myeloid leukemia in children with Down syndrome (ML-DS) enrolled on the AAML1531 clinical trial.

NCT00369317

Clinical Trial Information

Trial Number: NCT00369317 (ClinicalTrials.gov)

Disease Type:

Hematopoietic Neoplasm/Leukemia - Acute Myeloid Leukemia
Hematopoietic Neoplasm/Leukemia - Myelodysplastic Syndrome

Trial Title:

The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years

Study ID:

AAML0431

Images are available?:

Is this a NCI-MATCH Trial?:

Datasets Linked to Trial

Title	Description
NCT00369317-D1	NCT00369317-D1 is the only dataset associated with this publication. The dataset contains the CONSORT flow of patient enrollment, baseline characteristics, adverse events, MRD, cytogenetics, and primary outcome analyses for patients on AAML0431 as reported in the manuscript. Also, data for patients on A2971 are provided in order to compare brief baseline characteristics and outcome to patients on AAML0431.

Title

Description

NCT00369317-D1

NCT00369317-D1 is the only dataset associated with this publication. The dataset contains the CONSORT flow of patient enrollment, baseline characteristics, adverse events, MRD, cytogenetics, and primary outcome analyses for patients on AAML0431 as reported in the manuscript. Also, data for patients on A2971 are provided in order to compare brief baseline characteristics and outcome to patients on AAML0431.

Subscribe to Hematopoietic Neoplasm/Leukemia - Myelodysplastic Syndrome

Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security

U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov

NIH…Turning Discovery Into Health^®